{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T11:15:46Z","timestamp":1791803746006,"version":"4.3.4"},"reference-count":72,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Peripheral neuropathies are common conditions and can result in numbness, paresthesia, motor deficits, and pain. There is increasing evidence for the use of biomarkers as clinical indicators of the presence, severity, and prognosis of nerve lesions; however, biomarker identification has largely been focused on disorders of the central nervous system, and less is known about their role in the peripheral nervous system.<\/jats:p><\/jats:sec>Objective<\/jats:title>To assess blood-based biomarker concentrations associated with nerve involvement in patients with peripheral neuropathy compared with control participants.<\/jats:p><\/jats:sec>Data Sources<\/jats:title>Ovid, MEDLINE, Embase, and CINAHL were searched from inception to September 23, 2021.<\/jats:p><\/jats:sec>Study Selection<\/jats:title>Observational studies reporting on blood biomarkers in patients diagnosed with peripheral neuropathy were included. This review was preregistered on PROSPERO and followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA<\/jats:ext-link>) reporting guideline. Data were abstracted by 1 investigator and independently reviewed by a second.<\/jats:p><\/jats:sec>Data Extraction and Synthesis<\/jats:title>Data were meta-analyzed when at least 2 studies reported the same biomarker with comparable methodology. Fixed-effects models were used when only 2 studies were included; random-effects models were used when more than 2 studies were included.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The outcome of interest was concentration of biomarkers.<\/jats:p><\/jats:sec>Results<\/jats:title>This review included 36 studies reporting on 4414 participants, including 2113 control participants and 2301 patients with peripheral neuropathy with 13 distinct peripheral neuropathy diagnoses. Diabetic neuropathy was the most common neuropathy diagnosis (13 studies), followed by Charcot-Marie-Tooth disease (6 studies) and Guillain-Barre syndrome (6 studies). Overall, 16 different blood-based biomarkers associated with nerve involvement were evaluated. The most used were neurofilament light chain, S100B, brain-derived neurotrophic factor, and neuron-specific enolase. Patients with peripheral neuropathy demonstrated significantly higher levels of neurofilament light chain compared with controls (standardized mean difference [SMD], 0.93 [95% CI, 0.82 to 1.05];P<\/jats:italic>\u2009&amp;lt;\u2009.001). There were no significant differences in levels of S100B (SMD, 1.10 [95% CI, \u22123.08 to 5.28];P<\/jats:italic>\u2009=\u2009.38), brain-derived neurotrophic factor (SMD, \u22120.52 [95% CI, \u22122.23 to 1.19];P<\/jats:italic>\u2009=\u2009.40), or neuron-specific enolase (SMD, \u22120.00 [95% CI, \u22121.99 to 1.98];P<\/jats:italic>\u2009=\u2009.10) in patients with peripheral neuropathy compared with control participants.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>The findings of this systematic review and meta-analysis support the use of neurofilament light chain as a blood-based measure associated with the presence of neuronal injury in patients with peripheral neuropathy.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2022.48593","type":"journal-article","created":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T16:00:47Z","timestamp":1672156847000},"page":"e2248593","source":"Crossref","is-referenced-by-count":60,"title":["Types and Concentrations of Blood-Based Biomarkers in Adults With Peripheral Neuropathies"],"prefix":"10.1001","volume":"5","author":[{"given":"Joel","family":"Fundaun","sequence":"first","affiliation":[{"name":"Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Kolski","sequence":"additional","affiliation":[{"name":"Department of Physical Therapy and Human Movement Sciences, Northwestern University, Feinberg School of Medicine, Chicago, Illinois"},{"name":"Musculoskeletal Outpatient Department, Shirley Ryan AbilityLab, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Molina-\u00c1lvarez","sequence":"additional","affiliation":[{"name":"Area of Pharmacology, Nutrition, and Bromatology, Department of Basic Health Sciences, Universidad Rey Juan Carlos, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Baskozos","sequence":"additional","affiliation":[{"name":"Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annina B.","family":"Schmid","sequence":"additional","affiliation":[{"name":"Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,12,27]]},"reference":[{"issue":"1","key":"zoi221373r1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s10654-015-0094-6","article-title":"The epidemiology and risk factors of chronic polyneuropathy.","volume":"31","author":"Hanewinckel","year":"2016","journal-title":"Eur J Epidemiol"},{"issue":"6","key":"zoi221373r2","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1001\/jamaneurol.2022.0565","article-title":"The global burden of polyneuropathy\u2014in need of an accurate assessment.","volume":"79","author":"Elafros","year":"2022","journal-title":"JAMA Neurol"},{"issue":"16","key":"zoi221373r3","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1212\/WNL.0000000000001492","article-title":"Impairments and comorbidities of polyneuropathy revealed by population-based analyses.","volume":"84","author":"Hoffman","year":"2015","journal-title":"Neurology"},{"key":"zoi221373r4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/jns.2012.17.issue-s2","article-title":"Current issues in peripheral neuropathy.","volume":"17","author":"Brannagan","year":"2012","journal-title":"J Peripher Nerv Syst"},{"issue":"5","key":"zoi221373r5","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1370\/afm.577","article-title":"Evidence of nephropathy and peripheral neuropathy in US adults with undiagnosed diabetes.","volume":"4","author":"Koopman","year":"2006","journal-title":"Ann Fam Med"},{"issue":"9","key":"zoi221373r6","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1001\/jamaneurol.2019.1534","article-title":"Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis.","volume":"76","author":"Bridel","year":"2019","journal-title":"JAMA Neurol"},{"issue":"613","key":"zoi221373r7","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abg9922","article-title":"Axonal marker neurofilament light predicts long-term outcomes and progressive neurodegeneration after traumatic brain injury.","volume":"13","author":"Graham","year":"2021","journal-title":"Sci Transl Med"},{"issue":"6","key":"zoi221373r8","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/ana.v81.6","article-title":"Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis.","volume":"81","author":"Disanto","year":"2017","journal-title":"Ann Neurol"},{"issue":"1","key":"zoi221373r9","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/S1474-4422(08)70293-X","article-title":"Biomarkers in amyotrophic lateral sclerosis.","volume":"8","author":"Turner","year":"2009","journal-title":"Lancet Neurol"},{"issue":"1","key":"zoi221373r10","doi-asserted-by":"publisher","DOI":"10.1136\/bmjno-2021-000143","article-title":"Correlation between CSF and blood neurofilament light chain protein: a systematic review and meta-analysis.","volume":"3","author":"Alagaratnam","year":"2021","journal-title":"BMJ Neurol Open"},{"key":"zoi221373r11","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jclinepi.2021.02.003","article-title":"Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement.","volume":"134","author":"Page","year":"2021","journal-title":"J Clin Epidemiol"},{"issue":"11","key":"zoi221373r12","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1016\/j.spinee.2018.06.349","article-title":"The association between pro-inflammatory biomarkers and nonspecific low back pain: a systematic review.","volume":"18","author":"van den Berg","year":"2018","journal-title":"Spine J"},{"issue":"6220","key":"zoi221373r13","doi-asserted-by":"publisher","DOI":"10.1126\/science.1260419","article-title":"Proteomics: tissue-based map of the human proteome.","volume":"347","author":"Uhl\u00e9n","year":"2015","journal-title":"Science"},{"issue":"1","key":"zoi221373r15","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range.","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"zoi221373r16","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jclinepi.2016.01.002","article-title":"Extracting data from figures with software was faster, with higher interrater reliability than manual extraction.","volume":"74","author":"Jelicic Kadic","year":"2016","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"zoi221373r19","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/jrsm.12","article-title":"A basic introduction to fixed-effect and random-effects models for meta-analysis.","volume":"1","author":"Borenstein","year":"2010","journal-title":"Res Synth Methods"},{"issue":"5","key":"zoi221373r21","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.jcjd.2019.01.003","article-title":"Associations of serum S100B and S100P with the presence and classification of diabetic peripheral neuropathy in adults with type 2 diabetes: a case-cohort study.","volume":"43","author":"Afarideh","year":"2019","journal-title":"Can J Diabetes"},{"issue":"7","key":"zoi221373r22","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s00592-020-01508-6","article-title":"Low brain-derived neurotrophic factor protein levels and single-nucleotide polymorphism Val66Met are associated with peripheral neuropathy in type II diabetic patients.","volume":"57","author":"Azoulay","year":"2020","journal-title":"Acta Diabetol"},{"key":"zoi221373r23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.neulet.2013.10.067","article-title":"S100B as a glial cell marker in diabetic peripheral neuropathy.","volume":"558","author":"Celikbilek","year":"2014","journal-title":"Neurosci Lett"},{"issue":"4","key":"zoi221373r24","doi-asserted-by":"publisher","DOI":"10.7754\/Clin.Lab.2020.191220","article-title":"Identification of blood miR-216a, miR-377 and their target genes ANGPTL4, GAP-43 and serum of PPARG as biomarkers for diabetic peripheral neuropathy of type 2 diabetes.","volume":"67","author":"Li","year":"2021","journal-title":"Clin Lab"},{"issue":"11","key":"zoi221373r25","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.2337\/dc13-0590","article-title":"NSE, a potential biomarker, is closely connected to diabetic peripheral neuropathy.","volume":"36","author":"Li","year":"2013","journal-title":"Diabetes Care"},{"key":"zoi221373r26","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.imlet.2017.03.011","article-title":"sNCAM as a specific marker of peripheral demyelination.","volume":"185","author":"Niezgoda","year":"2017","journal-title":"Immunol Lett"},{"issue":"12","key":"zoi221373r27","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1007\/s40618-016-0509-6","article-title":"Does vitamin D have any role in the improvement of diabetic peripheral neuropathy in type 1 diabetic patients?","volume":"39","author":"Ozuguz","year":"2016","journal-title":"J Endocrinol Invest"},{"key":"zoi221373r28","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1196\/nyas.2008.1137.issue-1","article-title":"Measurement of circulating neuron-specific enolase mRNA in diabetes mellitus.","volume":"1137","author":"Sandhu","year":"2008","journal-title":"Ann N Y Acad Sci"},{"issue":"44","key":"zoi221373r29","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001908","article-title":"Serum phosphorylated neurofilament-heavy chain, a potential biomarker, is associated with peripheral neuropathy in patients with type 2 diabetes.","volume":"94","author":"Qiao","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"zoi221373r30","doi-asserted-by":"publisher","first-page":"5943","DOI":"10.12659\/MSM.909449","article-title":"Diagnostic significance of serum levels of nerve growth factor and brain derived neurotrophic factor in diabetic peripheral neuropathy.","volume":"24","author":"Sun","year":"2018","journal-title":"Med Sci Monit"},{"issue":"1","key":"zoi221373r31","article-title":"Deficits in systemic biomarkers of neuroinflammation and growth factors promoting nerve regeneration in patients with type 2 diabetes and polyneuropathy.","volume":"7","author":"Ziegler","year":"2019","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"12","key":"zoi221373r32","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1007\/s00125-021-05557-6","article-title":"Neuron-specific biomarkers predict hypo- and hyperalgesia in individuals with diabetic peripheral neuropathy.","volume":"64","author":"Morgenstern","year":"2021","journal-title":"Diabetologia"},{"issue":"6","key":"zoi221373r33","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1007\/s11033-014-3270-y","article-title":"Elevated neurofilament light chain (NFL) mRNA levels in prediabetic peripheral neuropathy.","volume":"41","author":"Celikbilek","year":"2014","journal-title":"Mol Biol Rep"},{"issue":"7","key":"zoi221373r34","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1002\/acn3.2019.6.issue-7","article-title":"p75 and neural cell adhesion molecule 1 can identify pathologic Schwann cells in peripheral neuropathies.","volume":"6","author":"Kim","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"issue":"3","key":"zoi221373r35","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1111\/ene.v28.3","article-title":"Plasma neurofilament light chain as a potential biomarker in Charcot-Marie-Tooth disease.","volume":"28","author":"Millere","year":"2021","journal-title":"Eur J Neurol"},{"issue":"6","key":"zoi221373r36","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1002\/mus.25124","article-title":"Plasma neurofilament heavy chain is not a useful biomarker in Charcot-Marie-Tooth disease.","volume":"53","author":"Rossor","year":"2016","journal-title":"Muscle Nerve"},{"issue":"6","key":"zoi221373r37","doi-asserted-by":"publisher","first-page":"e518","DOI":"10.1212\/WNL.0000000000004932","article-title":"Plasma neurofilament light chain concentration in the inherited peripheral neuropathies.","volume":"90","author":"Sandelius","year":"2018","journal-title":"Neurology"},{"issue":"1","key":"zoi221373r38","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/acn3.v7.1","article-title":"Transmembrane protease serine 5: a novel Schwann cell plasma marker for CMT1A.","volume":"7","author":"Wang","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"issue":"5","key":"zoi221373r39","doi-asserted-by":"publisher","first-page":"e489","DOI":"10.1212\/WNL.0000000000012266","article-title":"MicroRNAs as biomarkers of Charcot-Marie-Tooth disease type 1A.","volume":"97","author":"Wang","year":"2021","journal-title":"Neurology"},{"issue":"1","key":"zoi221373r40","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12974-020-01737-0","article-title":"Increased serum neurofilament light chain concentration indicates poor outcome in Guillain-Barr\u00e9 syndrome.","volume":"17","author":"Altmann","year":"2020","journal-title":"J Neuroinflammation"},{"issue":"11","key":"zoi221373r41","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1002\/acn3.v7.11","article-title":"Ratio and index of neurofilament light chain indicate its origin in Guillain-Barr\u00e9 Syndrome.","volume":"7","author":"K\u00f6rtvelyessy","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"issue":"46","key":"zoi221373r42","doi-asserted-by":"publisher","first-page":"74582","DOI":"10.18632\/oncotarget.v7i46","article-title":"Quantitative proteomics reveals Piccolo as a candidate serological correlate of recovery from Guillain-Barr\u00e9 syndrome.","volume":"7","author":"Mateos-Hern\u00e1ndez","year":"2016","journal-title":"Oncotarget"},{"key":"zoi221373r43","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1136\/jnnp-2020-323899","article-title":"Serum neurofilament light chain predicts long-term prognosis in Guillain-Barr\u00e9 syndrome patients.","volume":"92","author":"Mart\u00edn-Aguilar","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1-2","key":"zoi221373r44","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S0165-5728(97)00143-4","article-title":"Circulating fragments of myelin-associated alpha 6 beta 4 integrin in Guillain-Barr\u00e9 syndrome.","volume":"80","author":"Sessa","year":"1997","journal-title":"J Neuroimmunol"},{"key":"zoi221373r45","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102613","article-title":"Expression analysis of BDNF, BACE1 and their antisense transcripts in inflammatory demyelinating polyradiculoneuropathy.","volume":"47","author":"Ghafouri-Fard","year":"2021","journal-title":"Mult Scler Relat Disord"},{"issue":"5","key":"zoi221373r46","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.v11.5","article-title":"Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy.","volume":"11","author":"Hayashi","year":"2021","journal-title":"Brain Behav"},{"issue":"2","key":"zoi221373r47","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/jns.2019.24.issue-2","article-title":"Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy.","volume":"24","author":"van Lieverloo","year":"2019","journal-title":"J Peripher Nerv Syst"},{"issue":"4","key":"zoi221373r48","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/jns.v24.4","article-title":"Plasma neurofilament light chain concentration is increased and correlates with the severity of neuropathy in hereditary transthyretin amyloidosis.","volume":"24","author":"Kapoor","year":"2019","journal-title":"J Peripher Nerv Syst"},{"issue":"2","key":"zoi221373r49","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1080\/13506129.2019.1708716","article-title":"Plasma neurofilament light chain: an early biomarker for hereditary ATTR amyloid polyneuropathy.","volume":"27","author":"Maia","year":"2020","journal-title":"Amyloid"},{"issue":"3","key":"zoi221373r50","doi-asserted-by":"publisher","first-page":"e412","DOI":"10.1212\/WNL.0000000000011090","article-title":"Neurofilament light chain as a biomarker of hereditary transthyretin-mediated amyloidosis.","volume":"96","author":"Ticau","year":"2021","journal-title":"Neurology"},{"issue":"8","key":"zoi221373r51","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.3760\/cma.j.issn.0366-6999.20140202","article-title":"Myelin protein zero and its antibody in serum as biomarkers of n-hexane-induced peripheral neuropathy and neurotoxicity effects.","volume":"127","author":"Jia","year":"2014","journal-title":"Chin Med J (Engl)"},{"issue":"7","key":"zoi221373r52","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1016\/j.clinph.2021.03.016","article-title":"Critical illness polyneuropathy, myopathy and neuronal biomarkers in COVID-19 patients: a prospective study.","volume":"132","author":"Frithiof","year":"2021","journal-title":"Clin Neurophysiol"},{"issue":"7","key":"zoi221373r53","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1136\/annrheumdis-2017-212045","article-title":"Serum neurofilament light chain: a biomarker of neuronal injury in vasculitic neuropathy.","volume":"77","author":"Bischof","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"zoi221373r54","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1046\/j.1529-8027.2000.absjun-6.x","article-title":"Antibodies to neuroblastoma cells in rheumatoid arthritis: a potential marker for neuropathy.","volume":"18","author":"Salih","year":"2000","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"zoi221373r55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000977","article-title":"Analysis of antibody and cytokine markers for leprosy nerve damage and reactions in the INFIR cohort in India.","volume":"5","author":"Jadhav","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"issue":"10","key":"zoi221373r56","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1007\/s00415-020-09949-3","article-title":"Sural nerve biopsy: current role and comparison with serum neurofilament light chain levels.","volume":"267","author":"Mariotto","year":"2020","journal-title":"J Neurol"},{"issue":"1","key":"zoi221373r57","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/ana.25276","article-title":"Neurofilament light: a candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion.","volume":"84","author":"Benatar","year":"2018","journal-title":"Ann Neurol"},{"issue":"1","key":"zoi221373r58","doi-asserted-by":"publisher","first-page":"3400","DOI":"10.1038\/s41467-021-23620-z","article-title":"A multicentre validation study of the diagnostic value of plasma neurofilament light.","volume":"12","author":"Ashton","year":"2021","journal-title":"Nat Commun"},{"issue":"38","key":"zoi221373r59","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000022363","article-title":"Neurofilament light chain level in traumatic brain injury: a system review and meta-analysis.","volume":"99","author":"Gao","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"6509","key":"zoi221373r60","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1126\/science.aaz1776","article-title":"The GTEx Consortium atlas of genetic regulatory effects across human tissues.","volume":"369","author":"Aguet","year":"2020","journal-title":"Science"},{"issue":"10","key":"zoi221373r61","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","article-title":"Neurofilaments as biomarkers in neurological disorders.","volume":"14","author":"Khalil","year":"2018","journal-title":"Nat Rev Neurol"},{"issue":"6","key":"zoi221373r62","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.5114\/aoms.2015.56342","article-title":"Brain-derived neurotrophic factor and its clinical implications.","volume":"11","author":"Bathina","year":"2015","journal-title":"Arch Med Sci"},{"issue":"6","key":"zoi221373r63","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.tins.2015.04.003","article-title":"Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker.","volume":"38","author":"Yang","year":"2015","journal-title":"Trends Neurosci"},{"issue":"4848","key":"zoi221373r64","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1126\/science.3281256","article-title":"The neural cell adhesion molecule (NCAM) as a regulator of cell-cell interactions.","volume":"240","author":"Rutishauser","year":"1988","journal-title":"Science"},{"issue":"12","key":"zoi221373r65","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/S1474-4422(19)30354-0","article-title":"Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study.","volume":"18","author":"van der Ende","year":"2019","journal-title":"Lancet Neurol"},{"issue":"1","key":"zoi221373r66","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13195-019-0472-5","article-title":"Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer\u2019s disease.","volume":"11","author":"Weston","year":"2019","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"zoi221373r67","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1001\/jamaneurol.2019.3238","article-title":"Serum neurofilament light chain levels in patients with presymptomatic multiple sclerosis.","volume":"77","author":"Bjornevik","year":"2020","journal-title":"JAMA Neurol"},{"issue":"7335","key":"zoi221373r68","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1136\/bmj.324.7335.466","article-title":"Peripheral neuropathy.","volume":"324","author":"Hughes","year":"2002","journal-title":"BMJ"},{"issue":"22","key":"zoi221373r70","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1212\/WNL.0000000000001642","article-title":"Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis.","volume":"84","author":"Lu","year":"2015","journal-title":"Neurology"},{"issue":"4","key":"zoi221373r71","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/nrd2251","article-title":"Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers.","volume":"6","author":"Trusheim","year":"2007","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"zoi221373r72","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/nrneurol.2013.245","article-title":"The emerging agenda of stratified medicine in neurology.","volume":"10","author":"Matthews","year":"2014","journal-title":"Nat Rev Neurol"},{"key":"zoi221373r14","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions, Version 6.1","author":"Higgins","year":"2020"},{"key":"zoi221373r18","volume-title":"Doing Meta-Analysis in R: A Hands-on Guide","author":"Harrer","year":"2019"},{"key":"zoi221373r69","volume-title":"IDF Diabetes Atlas","author":"International Diabetes Federation","year":"2019","edition":"9th ed"},{"key":"zoi221373r17","unstructured":"R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing. Accessed November 14, 2022. https:\/\/www.R-project.org"},{"key":"zoi221373r20","unstructured":"Popay? J, Roberts? H, Sowden? A, . Guidance on the conduct of narrative synthesis in systematic review: a product from the ESRC Methods Programme. Accessed November 14, 2022. https:\/\/www.lancaster.ac.uk\/media\/lancaster-university\/content-assets\/documents\/fhm\/dhr\/chir\/NSsynthesisguidanceVersion1-April2006.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2799943\/fundaun_2022_oi_221373_1671208868.64276.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T02:06:07Z","timestamp":1728612367000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2799943"}},"subtitle":["A Systematic Review and Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2022,12,27]]},"references-count":72,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.48593","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,27]]}}}